ArticleBiotechnology reports (Amsterdam, Netherlands)2025
Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform.
Article in Biotechnology reports (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibodies (BsAbs), engineered to target multiple antigens or epitopes simultaneously, promise enhanced therapeutic efficacy over traditional monoclonal antibodies (mAbs). However, the complex BsAbs structure presents significant production challenges, particularly chain mismatch issues. This study presents a novel approach utilizing 2A peptides within a FaBody platform to address light chain mismatches in IgG-like BsAbs. By leveraging self-cleaving 2A peptides, stable expression in mammalian cells significantly improves the accuracy of antibody chain assembly. This strategy markedly enhances the production of correctly assembled IgG-like BsAbs, providing a promising solution to critical challenges in BsAbs drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.